NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36866
Issuer: Summit Therapeutics Inc.
Exchange: The Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 85B Park Drive
Abingdon, Oxfordshire,
UNITED KINGDOM
OX14 4RY
Telephone number: 617-294-6607
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
American Depositary Shares
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o 17 CFR 240.12d2-2(a)(1)
o 17 CFR 240.12d2-2(a)(2)
x 17 CFR 240.12d2-2(a)(3)
o 17 CFR 240.12d2-2(a)(4)
o  Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
o  Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements for the Securities Exchange Act of 1934, The Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2020-09-18ByTara PettaDirector
Date NameTitle
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024 Plus de graphiques de la Bourse Summit Therapeutics
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024 Plus de graphiques de la Bourse Summit Therapeutics

Actualités Summit Therapeutics Inc.

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mercredi 3 Juillet 2024 ( il y a 2 semaines) • Business Wire
Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
Jeudi 27 Juin 2024 ( il y a 3 semaines) • Business Wire
Form D - Notice of Exempt Offering of Securities
Mardi 18 Juin 2024 ( il y a 4 semaines) • Edgar (US Regulatory)
Form 8-K - Current report
Lundi 17 Juin 2024 ( il y a 4 semaines) • Edgar (US Regulatory)
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jeudi 13 Juin 2024 ( il y a 1 mois) • Edgar (US Regulatory)
Form 8-K - Current report
Lundi 3 Juin 2024 ( il y a 1 mois) • Edgar (US Regulatory)
Form 8-K - Current report
Lundi 3 Juin 2024 ( il y a 1 mois) • Edgar (US Regulatory)
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
Lundi 3 Juin 2024 ( il y a 1 mois) • Business Wire
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Samedi 1 Juin 2024 ( il y a 1 mois) • Business Wire
 Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
Samedi 1 Juin 2024 ( il y a 1 mois) • Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vendredi 31 Mai 2024 ( il y a 2 mois) • Business Wire
Form 8-K - Current report
Jeudi 30 Mai 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Plus d'articles sur Summit Therapeutics Inc.

Dernières Valeurs Consultées

LSE
ROLL
Is Bg Rl Cmt-u
LSE
AT1
Ivz At1 Capbond
Delayed Upgrade Clock